Researchers have reported evidence from the brain suggesting that the way in which a new mother copes with her new parenting duties and the care of her infant can contribute to her own mental health…
Read More
An investigational medicine called zuranolone has generated significant, rapid, and enduring symptom reduction in women with postpartum depression. The drug was compared with placebo in a phase 3…
Read More
Is it possible to disrupt the process by which a mother can transmit risk for psychiatric disorders to her offspring? New research suggests one way in which this may be possible.
Read More
Past research has established a clear connection between maternal depression and risk of adverse outcomes in newborns, for instance a higher risk of the child having low birthweight. Over the longer…
Read More
On March 19, 2019, the U.S. Food and Drug Administration approved the first-ever drug specifically designed to alleviate the symptoms of postpartum depression. The drug, called brexanolone, acts…
Read More
